183557-77-9

Basic information

• Product Name: (4-morpholin-4-yl-phenyl)-amide
• Synonyms: (4-morpholin-4-yl-phenyl)-amide
• CAS NO: 183557-77-9
• Molecular Weight: 206.244
• Mol File: 183557-77-9.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: (4-morpholin-4-yl-phenyl)-amide(CAS DataBase Reference)
• NIST Chemistry Reference: (4-morpholin-4-yl-phenyl)-amide(183557-77-9)
• EPA Substance Registry System: (4-morpholin-4-yl-phenyl)-amide(183557-77-9)

Safety Data

• Hazardous Substances Data: 183557-77-9(Hazardous Substances Data)

Usage

General Description

The chemical (4-morpholin-4-yl-phenyl)-amide is a compound containing a morpholine ring and a phenyl group linked to an amide functional group. It is often used as a building block in the synthesis of various organic compounds. The morpholine ring provides the molecule with unique properties, such as its ability to form hydrogen bonds and its relatively low reactivity. This chemical has potential applications in the pharmaceutical industry, where it could be used as a starting material for the development of drug candidates. Additionally, it may also find use in the production of specialty chemicals and materials. Further research and development may uncover additional uses for this compound in various fields.

Upstream product

• 7470-38-4 4-morpholin-4-yl-benzoic acid 
• 19614-15-4 4-(morpholin-4-yl)benzoic acid ethyl ester 
• 451-46-7 4-fluorobenzoic acid ethyl ester 
• 2835-68-9 4-aminobenzamide 
• 111-44-4 3-oxa-1,5-dichloropentane 
• 23676-05-3 4-morpholin-4-yl-benzoic acid methyl ester 
• 110-91-8 morpholine 
• 824-75-9 p-fluorobenzamide 
• 698-67-9 p-bromobenzamide 
• 10282-31-2 4-morpholinobenzonitrile 

Downstream Products

• 214759-74-7 1-(4-morpholin-4-ylphenyl)methanamine 
• 1542257-72-6 3-(2-(4-(morpholinyl)phenyl)thiazol-5-yl)-2,6-dimethylpyrimidine-4(3H)-one 
• 519056-60-1 4-(morpholino)thiobenzamide 
• 1542258-99-0 4-(4-(5-nitrothiazol-2-yl)phenyl)morpholine 
• 1542258-98-9 4-(4-(thiazol-2-yl) phenyl) morpholine 
• 1542259-00-6 2-(4-morpholinophenyl) thiazol-5-amine 

Relevant articles and documents

Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors

Starting from the phase II clinical FGFR inhibitor lucitanib (2), we conducted a medicinal chemistry approach by opening the central quinoline skeleton coupled with a scaffold hopping process thus leading to a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives. Compound 25a was identified to show selective and equally high potency against FGFR1/2 and VEGFR2 with IC50 values less than 5.0 nM. Significant antiproliferative effects on both FGFR1/2 and VEGFR2 aberrant cancer cells were observed. In the SNU-16 xenograft model, compound 25a showed tumor growth inhibition rates of 25.0% and 81.0% at doses of 10 mg/kg and 50 mg/kg, respectively, with 5% and 10%body weight loss. In view of the synergistic potential of FGFs and VEGFs in tumor angiogenesis observed in preclinical studies, the FGFR/VEGFR2 dual inhibitor 25a may achieve better clinical benefits.

NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS

The invention relates to the field of medicine, discloses new nitrogen heterocyclic derivatives, preparation method thereof and as medicament in particular as the treatment and prevention of treating tissue fibrosis of the medicament. The invention also discloses a pharmaceutically acceptable compound of the present invention comprise a pharmaceutical composition and methods for using the composition for the treatment of the human or animal tissue fibrosis of diseases, in particular for treating the human or animal renal interstitial fibrosis, glomerular sclerosis, hepatic fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, skin fibrosis, after the operation of adhering, benign prostate hypertrophy, bone-myocardial, scleroderma, multiple sclerosis, pancreas fibrosis, liver cirrhosis, myosarcoma, neurofibromatosis, interstitial pulmonary fibrosis, diabetic nephropathy, Alzheimer's disease or vascular fibrosis disease in use. (by machine translation)

Nitrogenous Heterocyclic Derivatives And Their Application In Drugs

The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.